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Abstract: Fructooligosaccharide (FOS) is a typical prebiotic agent. A randomized, double-masked, placebo-
controlled study was performed to evaluate the prebiotic effect of daily intake of an isotonic solution containing
FOS on body weight gain and the reduction of diarrhea in children in an urban slum in Bangladesh over six con-
secutive months. We enrolled a total of 150 children, aged 25-59 months. Sixty-four children in the FOS group re-
ceived 50 mL of isotonic solution with 2 g of FOS added, and 69 children in the placebo group were given an iden-
tical solution with 1 g of glucose added, once a day. The measurement of body weight was carried out every other
day; height and arm circumference were measured once a month; and the children’s mothers were interviewed to
obtain data about diarrhea, the consistency and constitution of stool, other symptoms, and antibiotic treatment. As
a result, the body weight gain during the six-month period was 0.86±0.55 kg in the FOS group and 0.89±0.48 kg
in the placebo group, while the increase in height and arm circumference were not significantly different between
the two groups. The number of diarrhea episodes during the six-month period was not significantly different. A
significant reduction in the duration of diarrhea days and of duration per episode was observed in the FOS group (p
=0.039 and p=0.008, respectively). In conclusion, daily intake of FOS was associated neither with the children’s
growth nor with the number of diarrhea episodes, but a significant reduction in the duration of diarrhea days was
observed. Further studies are needed to confirm the effects of FOS by changing the doses and eliminating the in-
fluence of antibiotics.
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INTRODUCTION
Diarrhea is a severe health problem that leads to mor-
tality among children in developing countries. Clinical stud-
ies have clarified that some nondigestible carbohydrates
with a molecular weight of more than 20,000 can alleviate
diarrhea [1-8]. Fructooligosaccharide (FOS) is a mixture of
1-kestose (GF2), 28%; nystose (GF3), 60%; and β-
fructofranosyl nystose (GF4), 12%; [9, 10]. It is completely
safe [7, 9], has a sweet taste, and is easy to dissolve due to
its small molecular weight (approximately 680). Prebiotics
have already been identified as nondigestible food ingredi-
ents that beneficially affect the host by selectively stimulat-
ing the growth or activity of one or more bacteria in the co-
lon [11, 12].
FOS is a typical nondigestible oligosaccharide and
prebiotic agent. It is not hydrolyzed by any intestinal en-
zymes, is well fermented in the large intestine in human
studies [13, 14], and improves the intestinal microflora in
such a way that it becomes difficult for pathogenic microbes
to proliferate in the human gastrointestinal tract [15-20].
The fermentation brings probiotic effects in vitro [21, 22],
in vivo [21, 23], and also in humans [21, 24]. Using [U-14C]
FOS Oku, et al. have already shown that more than 99% of
FOS is metabolized through fermentation by intestinal mi-
crobes [10, 25, 26]. The final products of fermentation are
gases and short chain fatty acids such as acetate, propionate,
and n-butyrate [10, 25, 27, 28]. Through the process of fer-
mentation, harmful products such as ammonia, phenol, ska-
tole, and indole are reduced due to the reduction of the en-
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zyme activity needed to synthesize these products [29, 30].
Furthermore, studies using animals and humans to de-
termine the interaction of FOS supplementation with gas-
trointestinal function [31, 32], growth [29], immune re-
sponse [33, 34], diarrhea in pigs [35], and traveler’s diar-
rhea [36] have been assessed. However, the effect of FOS
intake on the reduction of diarrhea and growth in children
in the community has not been clarified [37]. Our hypothe-
sis is that the daily intake of FOS-supplemented commer-
cially developed isotonic solution improves the intestinal
microflora and reduces diarrhea, thereby inducing an im-
provement in body weight gain in children. To assess the
prebiotic effect on body weight gain and on the reduction of
diarrhea, we performed a randomized, double-masked,
placebo-controlled study for six consecutive months with
children in an urban slum community of Bangladesh.
SUBJECTS AND METHODS
Study Population
The trial took place in Mirpur, an urban slum commu-
nity with 800 households in the city of Dhaka, Bangladesh
between December 2004 and June 2005. Mirpur is densely
populated and has poor sanitary and hygienic conditions.
Diarrhea is known as a serious health problem among chil-
dren in the slums of Dhaka. The International Center for
Diarrhea Diseases Research (ICDDR, B) has established a
demographic surveillance system in this area, and a sam-
pling frame was available. Children aged 25-59 months and
their mothers were recruited randomly based on the demo-
graphic database prepared by ICDDR, B. Children who
were being breast-fed, those who suffered from chronic di-
arrhea or malnutrition (weight-for-height z-score <-2), and/
or those who were receiving antibiotic therapy were ex-
cluded.
A total of 158 children were enrolled, but 8 out of 158
did not participate. Therefore, 150 children were randomly
assigned to each of two groups, the prebiotic (FOS) or the
placebo (glucose) group.
The trial was approved by the Ethical Committee of
Siebold University of Nagasaki Prefecture, and by the Ethi-
cal Review Committee of ICDDR, B. Informed consent was
obtained from all parents. The children were provided
medical care in the ICDDR, B-run clinic for any serious ill-
nesses during the study period. Oral rehydration therapy
was performed for most of the diarrhea cases observed.
Study Outcome
The primary study outcome was body weight gain and
a reduction in the number of diarrhea episodes. The secon-
dary outcome was a decrease in the cumulative duration of
diarrhea days, the duration of diarrhea days per diarrhea
episode, and the number of defecations per day during a di-
arrhea episode. According to the World Health Organiza-
tion [38], diarrhea is defined as the passage of three or more
loose or watery stools in a 24-h period. An episode of diar-
rhea was defined as a period beginning with a day when the
subject experiences more than three loose stools and ending
with the last diarrhea day followed by at least two consecu-
tive days without diarrhea. Severe diarrhea was defined as
either persistent or invasive diarrhea. Persistent diarrhea was
defined as having a duration of more than 14 days, while in-
vasive diarrhea was defined as diarrhea with macroscopic
blood.
Study Protocol
The intervention involved the daily intake for six con-
secutive months of commercially produced isotonic solu-
tion (Pocari Sweat, Otsuka Pharmaceutical Co., Ltd., Tokyo,
Japan) with the addition of fructooligosaccharide (FOS,
Meiji Seika Kaisha Ltd., Tokyo, Japan), the chemical struc-
ture of which is 1F-(β-fructofranosyl)n-1-sucrose, where n
varies from 2 to 4 (e.g., 2, 1-kestose (GF2), 28%; 3, nystose
(GF3), 60%; and 4, 1F-β-fructofranosyl nystose (GF4),
12%). The placebo group received an identical bottle of pla-
cebo solution with glucose (Nihon Shokuhin Kako CO.,
Ltd., Tokyo, Japan). FOS and glucose were of an analytical
grade. The commercially produced isotonic solution
masked the slight differences in both sweetness and taste
between the two solutions. In order to reduce the osmotic
pressure of the solution, 1.85 g of “Pocari Sweat” powder
was dissolved in 50 mL of water, and 2 g of FOS or 1 g of
glucose was added to achieve equal energy. The total os-
motic pressure was 0.234 Osmol/kg for the FOS solution
and 0.278 Osmol/kg for the glucose solution, measured by
the cryoscopy freezing-point method using the Osmometer
OM802 (Asahi Life Science Co., Ltd., Tokyo, Japan). The
main nutrients and the concentration of electrolytes in these
solutions are shown in Table 1. Forty mL of each test solu-
tion was freshly prepared every morning, and then 50 mL
was transferred to a bottle for each child.
Prior to the start of the trial, randomization was carried
out using the master randomization code, and two sets of
code envelopes were made by an independent statistician,
who was not involved in the study in any way. No collabo-
rator or field research assistant knew the group to which any
of the children belonged, or the content of any particular so-
lution bottle.
Four trained field research assistants and four health
attendants were recruited from the study area. A field re-
search assistant and a health attendant formed a team for
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teams distributed the test solution daily and directly admin-
istered it to each child. They interviewed the mother of
each child every day, and measured each child’s body
weight on alternative days. The interview questions were
the number of defecations, consistency and constitution of
stool (hard, loose, or watery; visible blood and/or mucus in
the feces), abdominal or other symptoms, and treatment and
administration of antibiotics. The research assistants con-
ducted their activities according to a manual using check-
lists. If the child was not at home, the mother was asked to
keep one bottle and to give it to the child within a day.
Body weight was measured using a digital scale with 0.1-
kg precision (UNI-scale). Height and arm circumference
were measured using a wooden perpendicular scale and a
TALC tape measure, respectively in the field clinical office
once a month. Measurements were carried out at least two
times.
Data Management and Statistical Analysis
The study releaved a 0.06 kg mean difference with a
0.12 kg standard deviation in body weight gain, based on
the assumptions from previous studies in Bangladesh [39,
40], using a two-sided alpha of 0.05 and a power of 80%.
The requirement of more than 63 children per group was es-
tablished, and assuming a 16.7% (20/120) drop-out rate, the
calculated number of children required for the study was 75
in each group.
Data were collected by the field research assistants ac-
cording to forms that were reviewed by the supervising staff
in ICDDR, B. Data were entered and checked logically and
in terms of range. Thereafter, cleaning and analysis were
performed using SPSS ver.11 for Windows, Japan (SPSS
Inc., Japan). For comparison of the categorical data, chi-
square or Fisher’s exact test was used. Continuous data
were compared with Student’s t’test for normally distrib-
uted data and the Welch or Mann-Whitney U test for non-
parametric data. Pearson’s correlation was used to evaluate
the relation of the number of diarrhea episodes or cumula-
tive days of diarrhea with the body weight gain. The data
were expressed as means and standard deviations with the
significance level considered to be less than 0.05.
RESULTS
Characteristics of Children at Baseline
The flow chart of randomization procedure is shown in
Figure 1. The characteristics of the participants initially al-
located to each group and those who completed the study
are shown in Table 2. The characteristics were not signifi-
cantly different for the initial groups. Age in the FOS group
(n=75) was 46.4±9.8 months, and that in the placebo
group (n=75) was 46.5±9.2 months. The number of chil-
dren who completed the study was 64 in the FOS group and
69 in the placebo group. The percentage of males was sig-
nificantly higher in the FOS group than in the placebo
group (p=0.037).
Dose Levels of FOS Administered
According to the field research assistants, all the chil-
dren liked to drink the solutions, and none refused the ad-
ministration. The average dose level of the administration
of FOS was 0.147±0.235 g per kg of body weight at the
start of the study period and 0.138±0.222 g per kg of body
weight at the end of the study.
Table 1. Nutrients and concentration of electrolytes in FOS and
placebo solutions
FOS solution Placebo solution
Nutrients (per 100 mL)
Energy (kcal) 16.0 16.0
Carbohydrate (g) 3.4 3.4
Protein (g) 0.0 0.0
Fat (g) 0.0 0.0
Added FOS (g) 4.0 0.0










Data were obtained from Otsuka Pharmaceutical Co., Ltd.
Figure 1. Flow chart of randomization procedure and attrition
of study participants
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Growth and the Number of Children Experiencing Di-
arrhea
Data on body weight gain after six months’ daily in-
take of the two kinds of test solutions are shown in Table 3.
The average body weight gain in the FOS group was 0.86±
0.55 kg, while that in the placebo group was 0.89±0.48 kg.
There were no significant differences in the increase in
body weight, height and arm circumference between either
the FOS and placebo groups or the males and females in
each group.
The number of children who experienced one or more
episodes of diarrhea was 39 out of 64 children in the FOS
group and 44 out of 69 children in the placebo group. The
difference between the groups was not significant. The
number of children experiencing persistent diarrhea was
only one in the FOS group and two in the placebo group.
The Number and Duration of Diarrhea Episodes
Table 4 shows the average number of diarrhea episodes,
the cumulative diarrhea days over the six-month period, the
duration of diarrhea per episode, and the number of defeca-
tions per day of diarrhea. The average number of diarrhea
episodes was 1.3±1.6 in the FOS group and 2.0±2.8 in
the placebo group. There were apparently fewer episodes
of diarrhea in the FOS group than in the placebo group, but
the difference was not significant.
The cumulative number of diarrhea days in the FOS
group was 3.3±4.9 days, significantly fewer than that in
Table 2. Characteristics of children at baseline: enrolled and analyzed
Initially allocated Completed study
FOS (n=75) Placebo (n=75) FOS (n=64) Placebo (n=69)
Age (mo) 46.5 (9.2) 46.4 (9.8) 46.5 (9.1) 46.3 (9.4)
Males (%) 52.0 38.6 53.1a 34.8
Body weight (kg) 12.8 (2.0) 12.6 (2.0) 12.9 (2.0) 12.6 (2.1)
Height (cm) 94.9 (8.6) 93.8 (7.8) 95.0 (8.3) 93.8 (8.1)
MUAC (cm) 15.0 (1.0) 15.1 (1.1) 15.0 (1.1) 15.1 (1.2)
FOS, fructooligosaccharide; MUAC, arm circumference. Values were expressed as mean and (standard deviation: S.D.). The number of
enrolled children was 150; a group of 75 children were allocated to the FOS-group, and the other 75 were to the placebo group. Sixty-
four children of the FOS-group and 69 children of the placebo group completed the study and their data were used for analysis. a: sig-
nificantly different from the placebo group, at p=0.037.
Table 3. Growth during the six-month period and the number of children who experi-
enced diarrhea
FOS (n=64) Placebo (n=69)
Body weight gain (kg) 0.86 (0.55) 0.89 (0.48)
Height gain (cm) 2.76 (0.71) 2.73 (0.68)
MUAC gain (cm) 0.24 (0.39) 0.27 (0.41)
Children reporting diarrhea (number)＊1 39 44
Children reporting persistent diarrhea (number)＊2 1 2
FOS, fructooligosaccharide; MUAC, arm circumference. Values were expressed as mean and (S.D.).
＊1: the number of children who experienced one or more episodes of diarrhea; ＊2: the number of chil-
dren who experienced persistent diarrhea. No difference was observed between the two groups.
Table 4. The comparison of diarrhea episodes between FOS and placebo groups
FOS (n=63) Placebo (n=67) p-values
Number of diarrhea episodes (number) 1.3 ( 1.6) 2.0 ( 2.8) 0.098
Cumulative diarrhea days 3.3 ( 4.9) 6.3 (10.8)a 0.039
Duration of diarrhea days per episode＊1 2.5 ( 1.8) 3.2 ( 2.4)b 0.008
Number of defecations per day of diarrhea＊1 2.5 ( 1.7) 2.2 ( 1.4) 0.096
Visible blood in feces (number) 1 1 1.000
Mucus in feces (number) 9 14 0.365
Values were expressed as mean and (S.D.). The total numbers (64 in FOS group, and 69 in placebo group) excluding persis-
tent diarrhea of FOS and placebo groups were 63 and 67, respectively. ＊1: n=84 in FOS group, and n=147 in FOS group, re-
spectively. a, b: significantly different from the placebo group, respectively.
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the placebo group (6.3±10.8 days), at p=0.039. The dura-
tion per diarrhea episode in the FOS group (2.5±1.8) was
also significantly shorter than that in the placebo group (3.2
±2.4), at p=0.008. However, the number of defecations
per days of diarrhea was not significantly different between
the FOS group (2.5±1.7) and the placebo group (2.1±1.4).
The number of children with macroscopic blood in fe-
ces was one in each group. Mucus in feces occurred in nine
children in the FOS group and 14 in the placebo group.
The difference was not statistically significant.
Other Symptoms and Antibiotic Treatment
The data on other symptoms were collected for 50 out
of 64 children in the FOS group and for 51 out of 69 chil-
dren in the placebo group, as shown in Table 5. Cough was
observed in 44 out of 50 children in the FOS group and 44
out of 51 children in the placebo group. The difference was
not significant. Most of the children experienced angular
stomatitis and ear discharge. Chloramphenicol antibiotic
treatment was administered to almost all of the children in
the two groups.
Association of Diarrhea with Body Weight Gain
The number of episodes and duration of diarrhea had
no significant correlation with body weight gain in either
the FOS (r=-0.092, r=-0.64) or placebo group (r=-0.088, r=
-0.44).
DISCUSSION
The prebiotic effect of daily FOS intake on growth and
on the episodes and duration of diarrhea was studied in
free-living children in an urban slum in Bangladesh. The
difference in growth between the FOS and placebo groups
was not significant, nor did the number of diarrhea episodes
differ between the two groups. Many factors other than the
prebiotic effect might directly and/or indirectly affect
growth and diarrhea. It has been reported that it is difficult
to detect the benefit of the prebiotic effect in healthy popu-
lations [36, 37].
Three factors may explain this. First, the dose of FOS,
on average 0.147 g per kg of body weight, might be too
small to reduce the number of diarrhea episodes. We se-
lected the dose on the basis of the following two points: 1)
dose transitory diarrhea can be completely avoided; and 2)
can promote the intestinal microflora. In adults, approxi-
mately 15 g of daily single intake (or 0.3 g per kg of body
weight) may induce hyperosmotic transitory diarrhea [26,
41, 42], and 1-2 g of daily single intake improved intestinal
microbes [15]. Considering that 0.5-2.5 g of nondigestible
oligosaccharides is supplemented to 100 g dry weight of
some brands of artificial formula milk in Japan (0.05-0.3 g
per 100 mL of formula solution), it may be possible to test
higher doses of FOS to examine the prebiotic effects in the
future. Further studies are needed to identify the optimal
dose level of FOS for children.
Secondly, most children were reported to have symp-
toms of cough, angular stomatitis, and/or ear discharge and
to be under treatment with chloramphenicol antibiotics,
which interfere with the proliferation of not only harmful
but also beneficial microbes [25, 27, 43, 44]. Chloram-
phenicol is a broad spectrum antibiotic, and it has been
shown to reduce intestinal microbes in rats [25]. The prebi-
otic effect might be disturbed by the use of antibiotics.
Thirdly, this study was conducted from the cool and
dry winter season to the hot and rainy season of Bangladesh.
Since many of the children had been treated with antibiotics
for respiratory infectious diseases in winter, the result may
have differed if the study had started in the rainy season.
On the other hand, the average number of days of diar-
rhea during the six-month period and the number of days of
diarrhea per episode were shorter in the FOS group than in
the placebo group. Intake of FOS may reduce the duration
of diarrhea in the children. But the shorter duration of diar-
rhea did not relate with weight gain, presumably because of
the effects of antibiotics. Further studies are required to de-
termine the prebiotic effect of FOS under conditions in
which antibiotics effects have been eliminated. The optimal
dose level and affordable administration methods of prebi-
otics for mitigating the disease burden of diarrhea should be
also studied.
In conclusion, daily intake of FOS was associated nei-
ther with the children’s growth nor with the number of diar-
rhea episodes, but a significant reduction in the duration of
diarrhea days was observed. Further studies are needed to
confirm the effects of FOS by changing the doses and elimi-
nating the influence of antibiotics.
Table 5. Other diseases, symptoms and antibiotic treatment dur-







Angular stomatitis 49 51
Ear discharge 50 51
Vomiting 15 18
Antibiotics treatment 50 51
No significant difference was detected between the two groups.
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